In recent weeks, questions have been raised regarding the safety profile of Zepbound, a popular weight-loss medication. Patients and legal professionals have pointed to a range of severe and potentially life-threatening side effects, sparking new scrutiny on the drug.
Zepbound, which contains the active ingredient tirzepatide, has a black box warning from the U.S. Food and Drug Administration (FDA) concerning the risk of thyroid tumors, including medullary thyroid carcinoma (MTC). While animal studies have shown a link, it is not yet known if the drug causes these tumors in humans. However, the official prescribing information advises against its use for individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Beyond the thyroid cancer warning, reports highlight other serious adverse events. Pancreatitis (inflammation of the pancreas) and gallbladder problems, such as gallstones and cholecystitis, have been reported in clinical trials and are listed as potential serious side effects. Severe gastrointestinal issues, including persistent nausea, vomiting, and diarrhea, have also been reported and can lead to dehydration, which may result in acute kidney injury.
The drug’s prescribing information also lists other severe risks, including serious allergic reactions, severe hypoglycemia (low blood sugar), changes in vision, and a potential for suicidal ideation. These safety concerns have led to legal claims and increased public discussion about the risks associated with the drug, emphasizing the importance of patient awareness and close medical supervision.
